Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AbbVie Inc. or Incyte Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AbbVie Inc. and Incyte Corporation compare based on key financial metrics to determine which better meets your investment needs.

About AbbVie Inc. and Incyte Corporation

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Latest Biotechnology and AbbVie Inc., Incyte Corporation Stock News

As of March 31, 2026, AbbVie Inc. had a $384.7 billion market capitalization, compared to the Biotechnology median of $254.1 million. AbbVie Inc.’s stock is down 4.8% in 2026, up 6% in the previous five trading days and up 5.94% in the past year.

Currently, AbbVie Inc.’s price-earnings ratio is 92.2. AbbVie Inc.’s trailing 12-month revenue is $61.2 billion with a 6.9% net profit margin. Year-over-year quarterly sales growth most recently was 10.0%. Analysts expect adjusted earnings to reach $14.536 per share for the current fiscal year. AbbVie Inc. currently has a 3.2% dividend yield.

As of March 31, 2026, Incyte Corporation had a $18.7 billion market cap, putting it in the 86th percentile of all stocks. Incyte Corporation’s stock is down 4.7% in 2026, up 3.9% in the previous five trading days and up 55.36% in the past year.

Currently, Incyte Corporation’s price-earnings ratio is 14.7. Incyte Corporation’s trailing 12-month revenue is $5.1 billion with a 25.0% net profit margin. Year-over-year quarterly sales growth most recently was 27.8%. Analysts expect adjusted earnings to reach $7.413 per share for the current fiscal year. Incyte Corporation does not currently pay a dividend.

How We Compare AbbVie Inc. and Incyte Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AbbVie Inc. and Incyte Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AbbVie Inc. and Incyte Corporation’s Quality Grades

Company	Ticker	Quality
AbbVie Inc.	ABBV	B
Incyte Corporation	INCY	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

AbbVie Inc. has a Quality Score of 61, which is Strong. Incyte Corporation has a Quality Score of 94, which is Very Strong.

The Quality Grade Winner: Incyte Corporation

As you can clearly see from the Quality Grade breakdown above, Incyte Corporation has a better overall quality grade than AbbVie Inc.. For investors who are looking for companies with higher quality than others in the same industry, Incyte Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbbVie Inc. and Incyte Corporation’s Momentum Grades

Company	Ticker	Momentum
AbbVie Inc.	ABBV	C
Incyte Corporation	INCY	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

AbbVie Inc. has a Momentum Score of 42, which is Average. Incyte Corporation has a Momentum Score of 68, which is Strong.

The Momentum Grade Winner: Incyte Corporation

As you can clearly see from the Momentum Grade breakdown above, Incyte Corporation is considered to have stronger momentum compared to AbbVie Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Incyte Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbbVie Inc. and Incyte Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AbbVie Inc.	ABBV	C
Incyte Corporation	INCY	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AbbVie Inc. has a Earnings Estimate Score of 59, which is Neutral. Incyte Corporation has a Earnings Estimate Score of 41, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither AbbVie Inc. or Incyte Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if AbbVie Inc. or Incyte Corporation is the better investment when it comes to estimate revisions.

Other AbbVie Inc. and Incyte Corporation Grades

In addition to Quality, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AbbVie Inc. and Incyte Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AbbVie Inc. or Incyte Corporation Stock?

Overall, AbbVie Inc. stock has a Momentum Score of 42, Estimate Revisions Score of 59 and Quality Score of 61.

Incyte Corporation stock has a Momentum Score of 68, Estimate Revisions Score of 41 and Quality Score of 94.

Comparing AbbVie Inc. and Incyte Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.